AHA 2025: Lp(a) and ASCVD, translating causal evidence into practice (Michelle O'Donoghue)

Michelle O'Donoghue (Brigham and Women's Hospital) on where the causal case for lipoprotein(a) now stands and what it means at the bedside: measure Lp(a) once in every adult's lifetime, use the result to sharpen risk stratification and to intensify the treatment of the modifiable risk factors around it, and watch the RNA-interference agents now in phase 3 outcomes trials. Recorded at AHA Scientific Sessions 2025 by Radcliffe Cardiology.